Clinical Trials Directory

Trials / Completed

CompletedNCT00823173

Exploratory Study on Topical ESBA105 in Acute Anterior Uveitis

An Open Label Exploratory Study to Assess the Safety, Tolerability and Clinical Activity of Topically Applied ESBA105 in Patients With Acute Anterior Uveitis

Status
Completed
Phase
Phase 2
Study type
Interventional
Enrollment
9 (actual)
Sponsor
ESBATech AG · Industry
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

The purpose of this study is to determine whether ESBA105, a topically applied TNF-alpha inhibitor, is safe and clinically active when applied to the eye of patients suffering from acute anterior uveitis

Detailed description

Acute anterior uveitis (AAU) is a common, recurrent disease characterized by inflammation of the iris and ciliary body. Though usually effectively treated by topical corticosteroids, novel treatment modalities are required to overcome the limitations and adverse effect problems associated with the use of corticosteroids. TNF-alpha has been recognized as a central disease mediator in AAU, as shown by preclinical models and clinical data with systemically applied TNF-alpha inhibitors. ESBA105 is a topically applied TNF-alpha inhibitor that is characterized by efficient penetration into the eye resulting in high intraocular drug levels. A recently completed Phase I trial confirmed that safety and tolerability of topical ESBA105 in healthy individuals is excellent and systemic exposure is low. In this pilot trial, the safety, local tolerability and clinical activity of topical ESBA105 in the treatment of patients with acute anterior uveitis shall be explored.

Conditions

Interventions

TypeNameDescription
BIOLOGICALESBA105ESBA105 eye drops (10mg/mL), initially applied in hourly dosing intervals, followed by later dose tapering (prolongation of dosing intervals)

Timeline

Start date
2009-01-01
Primary completion
2010-12-01
Completion
2010-12-01
First posted
2009-01-15
Last updated
2011-05-26

Locations

3 sites across 1 country: Germany

Source: ClinicalTrials.gov record NCT00823173. Inclusion in this directory is not an endorsement.